US Bancorp’s Kiniksa Pharmaceuticals KNSA Stock Holding History

US Bancorp’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.2K	Sell	770 -143	-16%	-$7.42K	﹤0.01%	2805
2026 Q1	$44K	Sell	913 -467	-34%	-$20.7K	﹤0.01%	2767
2025 Q4	$56.9K	Hold	1,380	–	–	﹤0.01%	2637
2025 Q3	$53.6K	Hold	1,380	–	–	﹤0.01%	2648
2025 Q2	$38.2K	Sell	1,380 -93	-6%	-$2.37K	﹤0.01%	2906
2025 Q1	$32.7K	Buy	+1,473	New	+$30.3K	﹤0.01%	2950
2024 Q2	–	Sell	-116	Closed	-$2.29K	–	4045
2024 Q1	$2.29K	Buy	+116	New	+$2.27K	﹤0.01%	3702
2023 Q2	–	Sell	-32	Closed	-$344	–	4063
2023 Q1	$344	Sell	32 -133	-81%	-$1.75K	﹤0.01%	3988
2022 Q4	$2.47K	Sell	165 -834	-83%	-$12.1K	﹤0.01%	3722
2022 Q3	$13K	Buy	+999	New	+$11.4K	﹤0.01%	3267
2022 Q2	–	Sell	-610	Closed	-$6K	–	4145
2022 Q1	$6K	Buy	+610	New	+$6.46K	﹤0.01%	3551

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

US Bancorp's KNSA Position: Q2 2026 in Review

US Bancorp reduced its Kiniksa Pharmaceuticals (KNSA) stake by 16% in Q2 2026, selling an estimated $7.42K and leaving 770 shares worth $49.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

US Bancorp first reported a position in KNSA in Q1 2022 and has held it in 11 quarters since. The position peaked at $56.9K in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

US Bancorp held 770 shares of Kiniksa Pharmaceuticals worth $49.2K as of Q2 2026.
US Bancorp sold 143 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $7.42K.
Kiniksa Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2805 holding.
US Bancorp first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
US Bancorp's Kiniksa Pharmaceuticals position peaked at $56.9K in Q4 2025.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.